There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Global Blood Therapeutics (GBT) and Vanda (VNDA) with bullish sentiments.
Global Blood Therapeutics (GBT)
In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Global Blood Therapeutics, with a price target of $83.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.3% and a 50.0% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, and Spero Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Global Blood Therapeutics with a $89.86 average price target, representing an 118.4% upside. In a report issued on November 1, Oppenheimer also assigned a Buy rating to the stock with a $74 price target.
.
See today’s analyst top recommended stocks >>
Vanda (VNDA)
Stifel Nicolaus analyst Derek Archila maintained a Buy rating on Vanda today and set a price target of $31. The company’s shares opened today at $21.64, close to its 52-week high of $23.50.
Archila wrote:
“We remain positive on VNDA’s execution on Hetlioz’s HPI initiative, which continues to deliver nice sales growth for the brand, and like the setup for the stock as we head into the end 2018 given two meaningful clinical catalysts (i.e. Magenis (SMS) and tradipitant for gastroparesis) for programs we do not believe VNDA gets much credit for. Overall, VNDA’s 3Q18 revs were in-line with our/consensus estimates and we are generally positive on the company’s execution thus far on its HPI initiative (now ~1 years old) which continues to demonstrate nice Q/Q growth. With that said, we believe investors are largely looking to top line readouts in 4Q18 as near-term drivers and we believe the risk/reward is skewed to the upside since we value VNDA’s base biz alone at $22, below where the stock is currently trading. We maintain our Buy rating and our TP moves to $31.”
According to TipRanks.com, Archila ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.0% and a 35.2% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Rhythm Pharmaceuticals Inc, and Pacira Pharmaceuticals.
Currently, the analyst consensus on Vanda is a Strong Buy with an average price target of $28.60, implying a 32.2% upside from current levels. In a report released today, Jefferies also initiated coverage with a Buy rating on the stock with a $26 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
